Overexpression of the p53 gene product has been observed in a high per
centage of malignant melanomas. To evaluate the role of this protein i
n the development of melanoma, we examined p53 expression in benign, p
remalignant, and malignant melanocytic lesions. Using the antibodies D
O-7 and 1801, which recognize both wild-type and most mutant forms of
the p53 protein, we analyzed by immunohistochemical staining 26 benign
nevi, 34 dysplastic nevi from patients at low risk for the developmen
t of melanoma, 22 dysplastic nevi from patients at high risk for the d
evelopment of melanoma, 61 primary melanomas (including 15 that arose
from dysplastic nevi), and 10 metastatic melanomas. Expression of the
p53 protein was not observed in any of the benign or dysplastic nevi.
Of the primary melanomas only 3 (5%) demonstrated nuclear staining, wh
ereas 70% of the metastatic melanomas showed a positive reaction for p
53. These data suggest that overexpression of the p53 gene product is
a late event in the progression of melanoma and consequently indicate
that expression of this protein cannot be used as a marker to identify
patients at high risk for the subsequent development of melanoma.